Current Price Action and Market Context
As of 5 Aug 2026, Glenmark Pharma’s stock closed at ₹2,219.00, marking a 1.85% increase from the previous close of ₹2,178.60. The intraday range saw a low of ₹2,200.35 and a high of ₹2,243.00, indicating moderate volatility within a relatively narrow band. The stock remains below its 52-week high of ₹2,471.05 but comfortably above the 52-week low of ₹1,794.00, reflecting resilience in the face of broader market fluctuations.
Technical Trend Evolution
The technical trend for Glenmark Pharma has transitioned from a sideways pattern to a mildly bullish one. This shift is primarily driven by daily moving averages, which currently exhibit a bullish crossover, signalling potential upward momentum in the near term. However, the weekly and monthly MACD (Moving Average Convergence Divergence) indicators remain mildly bearish, suggesting that the longer-term momentum has yet to fully confirm a sustained uptrend.
The KST (Know Sure Thing) oscillator, a momentum indicator that aggregates multiple rate-of-change calculations, also remains mildly bearish on both weekly and monthly timeframes. This divergence between short-term bullish signals and longer-term bearish momentum indicators highlights the complexity of Glenmark’s current technical setup.
Momentum and Volatility Indicators
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal, hovering in neutral territory. This indicates that the stock is neither overbought nor oversold, providing room for price movement in either direction without immediate risk of reversal due to extreme conditions.
Bollinger Bands present a mixed picture: weekly bands are bearish, suggesting price pressure near the lower band and potential volatility, while monthly bands are mildly bullish, indicating a longer-term tendency for price expansion upwards. This contrast further emphasises the need for investors to monitor short-term price action closely while considering the broader monthly trend.
Volume and Trend Confirmation
On the volume front, the On-Balance Volume (OBV) indicator is mildly bullish on the weekly chart, signalling that buying volume is slightly outweighing selling pressure in the short term. However, the monthly OBV remains neutral, implying that longer-term accumulation or distribution is not decisively favouring either bulls or bears.
Dow Theory assessments on both weekly and monthly timeframes indicate no clear trend, reinforcing the notion that Glenmark Pharma is in a transitional phase technically. This lack of definitive trend confirmation from Dow Theory suggests investors should exercise caution and await stronger signals before committing to significant positions.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Comparative Performance and Returns
Glenmark Pharmaceuticals has demonstrated robust returns relative to the Sensex over multiple time horizons. Year-to-date (YTD), the stock has gained 8.99%, significantly outperforming the Sensex’s negative return of -7.97%. Over one year, Glenmark posted a 6.99% gain compared to the Sensex’s -3.20%, underscoring its resilience amid broader market weakness.
Longer-term returns are even more impressive. Over three years, Glenmark’s stock has surged 176.18%, dwarfing the Sensex’s 19.34% gain. The five-year return stands at a remarkable 272.25%, compared to the Sensex’s 44.25%. Even over a decade, Glenmark’s 169.46% return is competitive, though slightly behind the Sensex’s 182.99%, reflecting strong growth in the mid-cap pharmaceutical space.
Mojo Score and Rating Update
MarketsMOJO currently assigns Glenmark Pharmaceuticals a Mojo Score of 65.0, categorising it with a Hold grade. This represents a downgrade from a previous Buy rating on 29 Jul 2026, reflecting the recent technical shifts and mixed indicator signals. The stock is classified as a mid-cap within the Pharmaceuticals & Biotechnology sector, which continues to attract investor interest due to its defensive qualities and growth potential.
Technical Indicator Summary
To summarise the technical indicators:
- MACD: Weekly and monthly charts remain mildly bearish, indicating caution on momentum strength.
- RSI: Neutral on weekly and monthly timeframes, suggesting no immediate overbought or oversold conditions.
- Bollinger Bands: Weekly bearish, monthly mildly bullish, reflecting short-term volatility against longer-term expansion potential.
- Moving Averages: Daily moving averages are bullish, signalling short-term upward momentum.
- KST: Mildly bearish on weekly and monthly charts, reinforcing the mixed momentum picture.
- Dow Theory: No clear trend on weekly or monthly charts, indicating technical indecision.
- OBV: Mildly bullish weekly, neutral monthly, suggesting moderate buying interest in the short term.
Investor Implications and Outlook
For investors, Glenmark Pharmaceuticals presents a nuanced technical profile. The shift to a mildly bullish trend on daily moving averages offers some optimism for near-term price appreciation. However, the persistence of bearish momentum indicators on weekly and monthly charts advises caution, as the stock has yet to confirm a sustained uptrend.
Given the mixed signals, investors may consider a measured approach, monitoring key support levels near ₹2,200 and resistance around ₹2,243. A decisive break above recent highs and improvement in MACD and KST readings could signal a stronger bullish phase. Conversely, failure to hold support levels may lead to renewed consolidation or downside risk.
Fundamentally, Glenmark’s strong relative returns versus the Sensex and its mid-cap status in a defensive sector provide a solid backdrop. The downgrade to Hold by MarketsMOJO reflects the current technical caution but does not negate the company’s longer-term growth prospects.
Glenmark Pharmaceuticals Ltd. or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Conclusion
Glenmark Pharmaceuticals Ltd. currently stands at a technical crossroads. While daily moving averages and short-term volume indicators hint at emerging bullish momentum, the broader weekly and monthly technical landscape remains cautious with mildly bearish momentum oscillators and neutral trend confirmations. Investors should weigh these mixed signals carefully, balancing Glenmark’s strong historical returns and sector fundamentals against the present technical uncertainty.
Continued monitoring of momentum indicators such as MACD and KST, alongside price action relative to moving averages and Bollinger Bands, will be critical in assessing the stock’s next directional move. For now, a Hold rating aligns with the current technical and fundamental outlook, pending clearer confirmation of trend strength.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
